Socioeconomic‐ and Insurance‐Based Inequities in Oncotype DX Testing and Score‐Guided Treatment
Cancer Medicine · 2025
DOI: 10.1002/cam4.71485 ↗At a glance
Journal article in Cancer Medicine, 2025. Written by Courtney P Williams and 6 co-authors. Institution: Division of General Internal Medicine & Population Science, University of Alabama at Birmingham, Birmingham, Alabama, USA. Major MEDLINE topics: Breast Neoplasms, Healthcare Disparities, Insurance Coverage, Insurance, Health. Cited 1 times so far (Crossref); 41 references. The full text is freely available (open access, CC BY 4.0). Funded by: Flatiron Health.
Abstract (original language)
Purpose
Personalized approaches to breast cancer treatment are increasingly guided by expensive, lab‐based genomic testing like Oncotype DX (ODX) Breast Recurrence Score Test. Little is known about how socioeconomic and insurance status may affect utilization of ODX testing and subsequent ODX score‐guided treatment.
Methods
This retrospective cohort study included women diagnosed with early‐stage, HR+/HER2‐ breast cancer from 2011 to 2023 within the US‐based, electronic health record (EHR)‐derived, deidentified Flatiron Health Research Database. Socioeconomic status was measured by a census block‐level measure of neighborhood deprivation. Insurance status was captured at the time of diagnosis. Utilization of ODX testing was compared descriptively. Age‐stratified likelihood of adjuvant chemotherapy by neighborhood deprivation or insurance status was estimated using relative risk, predicted probabilities, and 95% confidence intervals from adjusted Poisson models.
Results
Of 3814 patients eligible for ODX testing, 47% were commercially insured, and 31% lived in an impoverished neighborhood. Compared to those without, patients with an ODX test (47%, n = 1797) were more often white (81% vs. 74%), commercially insured (50% vs. 44%), or lived in an affluent neighborhood (72% vs. 66%). For patients aged ≤ 50 with low recurrence risk, patients who resided in affluent vs. impoverished neighborhoods had a 5% higher probability of receiving potentially inappropriate overtreatment with adjuvant chemotherapy. Of those with low/medium recurrence risk, publicly insured patients had more than double the probability of receiving adjuvant chemotherapy compared to those privately insured, suggesting potential overtreatment. For patients aged > 50 with ODX with high recurrence risk, Medicare beneficiaries had a 5% lower probability than privately insured patients and an 11% lower probability than Medicaid/Other beneficiaries of receiving recommended adjuvant chemotherapy, suggesting under treatment.
Conclusion
Socioeconomic‐ and insurance‐based inequities, including both overtreatment and undertreatment, were observed in this EHR‐based cohort of women with early‐stage breast cancer eligible for ODX testing, indicating opportunities to increase care quality.
Subjects
MeSH terms (MEDLINE)
Authors and institutions
- Division of General Internal Medicine & Population Science, University of Alabama at Birmingham, Birmingham, Alabama, USA.
- O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama, USA.
- Division of Hematology & Oncology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
- School of Nursing, University of Alabama at Birmingham, Birmingham, Alabama, USA.
ORCID profiles: Courtney P Williams, Gabrielle B Rocque
Funding
- Flatiron Health
Cite
APA
Williams, C. P., Shuey, J., El Dick, J., Jahan, N., Stringer-Reasor, E., Azuero, A., & Rocque, G. B. (2025). Socioeconomic‐ and Insurance‐Based Inequities in Oncotype DX Testing and Score‐Guided Treatment. Cancer Medicine. https://doi.org/10.1002/cam4.71485
Vancouver
Williams CP, Shuey J, El Dick J, Jahan N, Stringer-Reasor E, Azuero A, et al. Socioeconomic‐ and Insurance‐Based Inequities in Oncotype DX Testing and Score‐Guided Treatment. Cancer Medicine. 2025. doi:10.1002/cam4.71485
BibTeX
@article{Williams2025,
author = {Williams, Courtney P and Shuey, Jessica and El Dick, Joud and Jahan, Nusrat and Stringer-Reasor, Erica and Azuero, Andres and Rocque, Gabrielle B},
title = {Socioeconomic‐ and Insurance‐Based Inequities in Oncotype DX Testing and Score‐Guided Treatment},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.71485}
}
EUVIMED